Latest News & Features
Big Pharma
The patentability of any claims directed to the use of CRISPR technology in human embryo-like structures and human reproductive cells is far from certain, as Duncan Ribbons and Maeve Lynch of Redd explain. 12 November 2015
Europe
Philip Webber, partner at Dehns Patent & Trademark Attorneys, looks at the clarity of the language used in the Broad Institute of MIT and Harvard’s granted European patents for the CRISPR technology and questions whether it satisfies the European Patent Office’s requirements. 29 October 2015
Americas
Oppositions to a patent covering the CRISPR/Cas9 system illustrate the need for applicants to carefully consider making statements on commercially important technology even after a patent application has been filed. Catherine Coombes of law firm HGF reports. 29 October 2015
Asia-Pacific
Pharmaceutical trademark owners in Australia should carefully select and register their marks to minimise potential problems associated with including INNs or INN stems, as Geordie Oldfield of Dennemeyer explains. 27 October 2015
Big Pharma
UK court decisions in Warner-Lambert v Actavis seek to define second medical use patent rights, and the recent full trial ruling provides some early guidance on the ‘reasonable foreseeability’ test concerning patent use, says Steve Smith of Potter Clarkson. 27 October 2015
Americas
The future of Brazil’s technological innovation centres, which bring together public and private sector parties to develop mainly life sciences technology, looks bright. Gabriel Di Blasi and Felipe Barros Oquendo of Di Blasi, Parente & Associados report 27 October 2015
Asia
Parties can apply for a compulsory licence in India on several grounds, including that the invention is not worked in the country. Neeti Wilson of Anand and Anand explores the issue further. 27 October 2015
Americas
Despite the US Court of Appeals for the Federal Circuit’s ruling in Amgen v Sandoz, significant uncertainty concerning two key
provisions of the BPCIA remains, as Steve Coyle and Leslie-Anne Maxwell of Cantor Colburn describe. 27 October 2015
Americas
Patent examiners not only have to tackle legal questions, but in cases of inventions directed to genetically modified animals they must consider moral issues too. This forms part of a wider controversial debate surrounding animals and patents. LSIPR reports. 27 October 2015
Americas
Lawyers have claimed that the latest ruling in Ariosa Diagnostics v Sequenom creates an “existential threat” to biomedical patents in the US, but is this really the case? LSIPR investigates. 27 October 2015